Association of the lipoprotein lipase (LPL) gene S447X variant with hypertension has been investigated extensively, whereas the results are often irreproducible. We therefore conducted a meta-analysis to examine whether S447X variant was associated with hypertension and blood pressure variation. Case-control reports published in English language and humans were identified from MEDLINE, EMBASE and Web of Science search engines as of 10 December 2009. Fixed-effects model was applied to pool data in the absence of between-studies heterogeneity, and random-effects model otherwise. A total of five studies (960 cases and 1145 controls) for hypertension and four studies (n ¼ 2777) for blood pressure were included. Compared with 447SS homogeneous carriers, those with 447X variant had a lower risk of hypertension (odds ratio (OR) ¼ 0.78; 95% confidence interval (CI): 0.62-0.98; P ¼ 0.03), and this effect reached significance under the fixed-effects model (I 2 ¼ 30% and P ¼ 0.22). Similarly, compared with 447S allele carriers, those with 447X allele carriers also had a lower risk of hypertension (OR ¼ 0.79; 95% CI: 0.64-0.98; P ¼ 0.03). In case of pregnancy-induced hypertension, no significance was observed (P40.05). As for blood pressure association, there was no significant difference between 447X variant and 447SS homogeneous carriers for both systolic and diastolic blood pressure in the whole population, even stratified by gender (P40.05). The Egger test told no publication bias for all associations. This meta-analysis demonstrated that LPL gene S447X variant was significantly associated with hypertension and showed no obvious relation with pregnancy-induced hypertension and blood pressure variation.
Introduction
Currently, global awareness on the escalating threat of hypertension to public health has been enhanced. Hypertension is well described as the 'silent killer' as it can sneak up on a person over years with few noticeable symptoms, yet can cause a major damage to body organs or kill with a suddenness that takes a person's family by surprise. 1 The prevention of hypertension is thus an important public goal. 2 Usually, one of the practical attempts is to identify the hypertension-susceptibility genes that entails a specific physiological or biological function. 3 The lipoprotein lipase (LPL) gene is a logical candidate that has been extensively investigated in association with a series of clinical end points including, for example, myocardial infarction, 4, 5 ischaemic stroke, 6 hypertriglyceridaemia, 7 diabetic nephropathy, 8 hypertension 9, 10 and so on. In particular, a non-synonymous mutation in exon 9 of LPL gene, Ser447Ter (S447X), attracts special interest mainly considering its biological peculiarity because this biallelic change results in a truncated protein lacking two amino acids (Ser-Gly) at the carboxy terminus, 11 and usually the corresponding protein product is non-functional. Currently, numerous investigators have linked LPL gene S447X variant to hypertension or blood pressure from the aspects of biological, genetic and clinical significance. [12] [13] [14] Therefore, one effective strategy is to perform genetic association studies with the repeated use of the same variant(s) among different populations. Although a number of such studies have been conducted, the results are not often reproducible. Some studies suggested an association between the 447X variant and low hypertension risk or decreased blood pressure, [15] [16] [17] whereas other studies found no association at all. 18, 19 In retrospect, individual studies with small sample sizes that are known to have low statistical power limited the identification of genetic variability and yielded poor replication record. To systematically overcome this limitation, we metaanalysed all available case-control studies reported in English language aiming to examine the association of LPL gene S447X variant with hypertension. In addition, to quantitatively address this issue, we focused on the continuous blood pressure panel to compare its averaged values between 447SS homogeneous carriers and 447X variant carriers in this meta-analysis.
Methods

Literature search
We searched the MEDLINE, EMBASE and Web of Science engines for publications with the last update on 10 December 2009 using the keywords of 'hypertension' or 'blood pressure' and 'lipoprotein lipase' or 'LPL', along with 'gene' or 'variant' or 'mutation' or 'polymorphism' or 'alleles' or 'genotype'. We also checked the related articles and the reference lists of all retrieved studies for the relevant publications that were not identified initially. In case of multiple publications from the same population, we extracted those with the complete information. In addition, we restricted the search results to articles published in English language and studies in humans.
Inclusion/exclusion criteria
We brought all prevalent case-control studies into the meta-analysis regardless of sample size if (i) they aimed to examine the association of S447X variant with hypertension or blood pressure variation among unrelated subjects; (ii) they applied validated genotyping method for S447X variant; (iii) they provided sufficient information on the genotype/ allele counts or frequencies for estimating the effect measure (odds ratio (OR) or mean difference) and its corresponding confidence interval (CI). All ORs were calculated against healthy controls and all mean differences against 447SS homogeneous carriers. Hypertension was defined as averaged systolic blood pressure (SBP) readings exceeding 140 mm Hg or diastolic blood pressure (DBP) exceeding 90 mm Hg or treatment with anti-hypertensive medication. , where n is the number of subjects studied).
Data extraction
Statistical analysis
Meta-analysis was conducted using the Review Manager (RevMan) software (version 5.0.19) (http://www.cc-ims.net/revman/download). HardyWeinberg equilibrium was assessed by w 2 -test in controls for studies without track record. As the homogeneous carriers of S447X minor allele were relatively few, those with the 447X variants (447SX þ XX genotypes) were combined into a single group, and thus the dominant model was investigated. As for hypertension as a binary trait, contrasts of LPL gene 447SX þ XX versus 447SS, as well as 447X versus 447S were expressed in the form of OR and 95% CI. As for the continuous blood pressure values, mean differences of SBP and DBP in 447X variant carriers were compared against that in 447SS homogeneous carriers.
The presence of between-studies heterogeneity was calculated using the w 2 -based Cochran's Q statistic with statistical significance at the level of 0.10 as this statistic is proved to have poor power if there are few studies. 20, 21 In addition, the I 2 statistic was documented for the percentage of the observed between-study variability due to heterogeneity rather than chance with the ranges of 0-100% (I 2 ¼ 0-25%, no heterogeneity; I 2 ¼ 25-50%, moderate heterogeneity; I 2 ¼ 50-75%, large heterogeneity; I 2 ¼ 75-100%, extreme heterogeneity). 21 A fixed-effects model using Mantel-Haenszel method was applied in the absence of betweenstudies heterogeneity, and a random-effects model otherwise.
In addition, to provide more information, we performed the sensitivity analysis by removing an individual study each time to assess the influence of each study. Publication bias was assessed by the Egger test for each meta-analysis and it was calculated using the Stata software (version 9.0).
Results
Study characteristics
Through the first round extensive search, a total of 21 publications were identified in an effort to examine association of LPL gene variants with hypertension or blood pressure variation. Therefore, there were 12 studies that failed to meet our inclusion/exclusion criteria, including one review article, 22 two population studies, 23, 24 three studies investigating other variants in LPL gene [25] [26] [27] and six linkage studies. 13, 14, [28] [29] [30] Among the remaining, there were five eligible studies for association of S447X variant with hypertension as a binary trait 9, [17] [18] [19] 31 and four eligible studies for association of this variant with blood pressure variation. 10, 15, 16, 32 The baseline characteristics of these eligible studies are summarized in Table 1 (for categorical hypertension association) and Table 2 (for continuous blood pressure association), respectively.
For hypertension association studies, the genotype distributions of LPL gene S447X variant were in line with the Hardy-Weinberg equilibrium in controls at significance level of 0.05 for four hypertension association studies (not available in one study 17 ) . Except for two studies investigating the pregnancy-induced hypertension, 9, 19 others included subjects with the mean age of 445 years in both cases and controls. The sample sizes ranged from 50 to 497 in cases and from 50 to 501 in controls. The minor allele (447X) frequencies ranged from 5.4 to 12.8% in cases and from 8.6 to 12.8% in controls.
For blood pressure association studies, the average age values were appropriately 440 years in both males and females for S447X genotype carriers. Gender-stratified BP levels were available in three 10, 15, 16 (of the four) studies; we decided to perform a gender-specific meta-analysis with these cohorts. In addition, we analysed only three studies reporting the blood pressure in the whole population (both genders). 10, 16, 32 Meta-analysis for hypertension association Compared with the 447SS homogeneous carriers, those with the 447X variant (SX þ XX) had a lower risk of hypertension (pooled OR ¼ 0.78; 95% CI: 0.62-0.98; P ¼ 0.03), and this effect reached significance under the fixed-effects model (I 2 ¼ 30% and P ¼ 0.22 for w 2 -test) (Figure 1 ). Although the first initial study 18 covered the highest study weight (40.9%), it showed no association (OR ¼ 0.82; 95% CI: 0.58-1.17) with its right-hand CI bestriding the vertical unity line, and the following studies, especially the study (OR ¼ 0.34; 95% CI: 0.14-0.78) by Chen et al., 31 strengthened the effect of the initial study.
As the study by Salah et al. 17 provided only pooled 447SX þ 447XX genotype count, we thus excluded this study under the allelic model. Compared with the 447S allele carriers, those with the 447X allele carriers also had a lower risk of hypertension (pooled OR ¼ 0.79; 95% CI: 0.64-0.98; P ¼ 0.03) (Figure 2) . In a sensitivity analysis, after excluding two studies for pregnancy-induced hypertension, 9, 19 we observed an even lower risk for both genotype (pooled OR ¼ 0.69; 95% CI: 0.51-0.93; P ¼ 0.02) and allele (pooled OR ¼ 0.67; 95% CI: 0.50-0.91; P ¼ 0.01) comparisons. Conversely, after only retaining those with pregnancy-induced hypertension, 9, 19 we failed to find any suggestive association (for genotype, pooled OR ¼ 0.92; 95% CI: 0.65-1.30; P ¼ 0.64; and for allele, pooled OR ¼ 0.94; 95% CI: 0.69-1.29; P ¼ 0.71) (data not shown).
Meta-analysis for blood pressure association
Owing to the small number of 447XX genotype in each study, information on SBP and DBP levels was provided on the basis of pooled 447SX þ 447XX genotype, and thus here only dominant model was analysed for blood pressure association. As shown in Figures 3 and 4 , in the whole population including both genders, those with the 447X variant carriers had relatively lower SBP (mean difference ¼ À1.85; 95% CI: À6.06-2.37 mm Hg; P ¼ 0.39) and DBP (mean difference ¼ À2.21; 95% CI: À6.27-1.84 mm Hg; P ¼ 0.39) levels compared with the 447SS homogeneous carriers, whereas no significance was noted for both associations under the random-effects model (P for heterogeneity ¼ 0.07 and 0.007, respectively).
On stratification by gender, the similar and nonsignificant association persisted for both males and females, whereas this effect was alleviated for both SBP and DBP levels (data not shown). For example, in males, those with the 447X variant carriers had relatively lower SBP (mean difference ¼ À1.03; 95% CI: À4.14-2.08 mm Hg; P ¼ 0.52) and DBP (mean difference ¼ À0.13; 95% CI: À2.02-1.77 mm Hg; P ¼ 0.89) levels compared with the 447SS homogeneous carriers.
Publication bias
To assess publication bias, we run the Egger test (weighted regression) for each meta-analysis. There was no significant bias for all comparisons. For example, the coefficients for genotype and allele associations were À1.44 (s.e. ¼ 1.46; P ¼ 0.398) and 0.37 (s.e. ¼ 3.05; P ¼ 0.914), respectively.
Discussion
The most noteworthy finding of this meta-analysis was that the 447SX þ XX genotype and 447X allele consistently appeared to be significantly associated with a reduced risk of hypertension. Moreover, this significance vanished after restricting studies to pregnancy-induced hypertension. Contrastingly, we failed to observe significant reductions of blood pressure (SBP and DBP) levels for the 447X variant carriers as compared with the 447SS homogeneous carriers. To the best of our knowledge, this study represents the first systematic analysis for investigating the association of LPL gene S447X variant with both hypertension and blood pressure variation.
Mounting evidence suggests that patients with elevated blood pressure tend to have a high prevalence of lipid or lipoprotein abnormalities. 33, 34 The genomic sequence of LPL gene is highly polymorphic; it is thus of added interest to identify which variant(s) at this gene might have a functional potential to affect the final bioavailability of LPL. The S447X variant is just one of these potential candidates, as its mutation results in a truncated protein, and evidence from in vitro experiments suggested that this truncated LPL protein produces greater activity 35 or higher production 36 than its native form. The association of LPL gene S447X variant with hypertension or blood pressure variation has been widely evaluated, yet the results were inconsistent. It has been proposed that to generate robust association, a much larger sample involving 41000 subjects in each group might be required. In this regard, the meta-analysis is proven to be more powerful in estimating the true effect size than a single study.
To generate more information, we thus metaanalysed all relevant studies that aimed to investigate association of S447X variant with hypertension and blood pressure variation in the literature, and we interestingly observed that the S447X variant was significantly associated with hypertension, but not with pregnancy-induced hypertension and blood pressure variation. Pregnancy-induced hypertension is defined as the development of new arterial hypertension in a pregnant women after 20 weeks gestation, which is also suggestive of resulting from genetic determinants and environmental and their interactions. 37 Although several studies have attempted to link LPL gene S447X variant to hypertension, available literature and present metaanalysis for pregnancy-induced hypertension consistently showed the null results, leaving no suggestive evidence for the involvement of S447X variant in susceptibility to pregnancy-induced hypertension. Besides this, with regard to hypertension and blood pressure, several possibilities can be inferred here.
First, the LPL genetic profile might be different between Asians and Caucasians. For example, the frequencies of LPL gene 447X allele in hypertensive patients were nearly doubled among Caucasians (10.2%) as compared with Asians (mainly Chinese) (5.4-6.6%), suggesting a possible role of ethnic differences in genetic backgrounds and the environment that they lived in. 38 Second, LPL gene S447X variant are of small effect in the pathogenesis of hypertension. Although our sample size of 42000 subjects is not small, it may not be large enough to detect genes that contribute to blood pressure regulation through small effects. Third, the S447X variant might interact with other genetic variants in or near LPL gene or environment determinants such as dietary salt to produce the final disease phenotype, such as high blood pressure. For example, Li et al. 18 focused on three variants including S447X in LPL gene and observed significant association of LPL gene haplotypes, but not single locus, with hypertension in Han Chinese. Fourth, as there was no overlap for the included references between hypertension as a binary trait and continuous blood pressure form, it is possible that different population constitution (for hypertension association, mainly Asians and for blood pressure association, mainly Caucasians) and different lifestyle background might account for this discrepancy observed in our meta-analysis. We agree that confirmation of our results in a large, well-designed study is critical.
The present meta-analysis should be interpreted within the context of its limitations. First, this meta-analysis only focused on papers published in English language; reports in other languages might confound the present results. Second, the crosssectional nature of our included studies precludes comments on causality. Third, owing to the relatively small number of the eligible studies, we were unable to perform subgroup analyses by ethnicity, which might confound our results. Fourth, we cannot retrieve lifestyle information such as smoking and salt consumption, which can serve as effective modulators for the development of hypertension. Fifth, given the rather small number of studies included in our meta-analysis, the Egger test has only limited sensitivity to detect publication bias, which therefore cannot definitely be ruled out. Moreover, although there are huge meta-analyses incorporating the genome-wide association data, the false-positive signals resulting from multiple testing tingled most of these studies. To provide more convincing results, more candidate-gene studies are needed to increase our capacity to uncover these associations in the meta-analysis. Last but not the least, considering the complex genetic network within or between LPL gene and others that operate in the same pathway, the potential role of S447X variant might be diluted or masked by other genegene or gene-environment interactions. Therefore, the jury must remain out before the eventual truth prevails.
In summary, we extended previous findings on association of LPL gene S447X variant with hypertension and blood pressure by showing that this variant was significantly associated with hypertension as a binary trait and showed no obvious relationship with pregnancy-induced hypertension and blood pressure variation in this meta-analysis.
What is known about topic K A non-synonymous mutation in exon 9 of LPL gene, Ser447Ter (S447X), attracts special interest because this biallelic change results in a truncated protein lacking two amino acids (Ser-Gly) at the carboxy terminus.
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K Association of the LPL gene S447X variant with hypertension has been investigated extensively, whereas the results are often irreproducible. [15] [16] [17] [18] [19] K In retrospect, individual studies with small sample sizes that are known to have low statistical power limited the identification of genetic variability and yielded poor replication record.
What this study adds K To the best of our knowledge, this study represents the first systematic analysis for investigating the association of LPL gene S447X variant with both hypertension and blood pressure variation. K The 447SX+XX genotype and 447X allele appeared to be consistently and significantly associated with a reduced risk of hypertension, but not with pregnancy-induced hypertension. K We failed to observe significant reductions of blood pressures (SBP and DBP) for those with the 447X variant carriers compared with the 447SS homogeneous carriers.
